<DOC>
	<DOCNO>NCT01753362</DOCNO>
	<brief_summary>The purpose study examine effect liraglutide ( drug use treat type 2 diabetes ) glucose ( sugar ) control 26 week study period use addition insulin .</brief_summary>
	<brief_title>Liraglutide In Overweight Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 ) Type 1 Diabetes continuous subcutaneous insulin infusion ( CSII ; also know insulin pump ) multiple ( four ) injection insulin per day . 2 ) Using continuous glucose monitoring device ( CGM ) regularly measure blood sugar four time daily . 3 ) HbA1c le 8.5 % . 4 ) Well versed carbohydrate counting . 5 ) Age 1875 year 6 ) BMIâ‰¥ 25kg/m2 7 ) Age diagnosis type 1 diabetes &lt; 30 year . 8 ) evidence autoimmunity beta cell ( GAD65 islet cell antibody screen ) 1 ) Type 1 diabetes less 6 month ; 2 ) Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week ; 3 ) Hepatic disease ( transaminase &gt; 3 time normal ) cirrhosis ; 4 ) Renal impairment ( serum eGFR &lt; 30ml/min/1.73m2 ) ; 5 ) HIV Hepatitis B C positive status ; 6 ) Participation concurrent clinical trial ; 7 ) Any lifethreatening , noncardiac disease ; 8 ) Use investigational agent therapeutic regimen within 30 day study . 9 ) history pancreatitis 10 ) pregnancy 11 ) inability give inform consent 12 ) history gastroparesis 13 ) history medullary thyroid carcinoma MEN 2 syndrome . 14 ) Smokers advise change amount smoke duration study ; 15 ) Use agent insulin treatment diabetes ( metformin , pramlintide thiazolidinediones .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>